A version of this story appeared in the On Background newsletter from The Washington Times. Click here to receive On Background delivered directly to your inbox each Friday.
House Majority Leader Steve Scalise, the No. 2 Republican in the House, announced on Tuesday that he has been diagnosed with multiple myeloma, a type of blood cancer.
Mr. Scalise, Louisiana Republican, said in a statement that after not feeling like himself the past week, he underwent blood tests that revealed irregularities that resulted in the “very treatable” cancer diagnosis.
He said he has begun treatment, but will continue working and expects to return to Washington.
“I have now begun treatment, which will continue for the next several months,” said Mr. Scalise, 57. “I expect to work through this period and intend to return to Washington, continuing my work as Majority Leader and serving the people of Louisiana’s First Congressional District.”
“I am incredibly grateful we were able to detect this early and that this cancer is treatable,” Mr. Scalise said. “I am thankful for my excellent medical team, and with the help of God, support of my family, friends, colleagues, and constituents, I will tackle this with the same strength and energy as I have tackled past challenges.”
Multiple myeloma is a type of blood cancer that forms in plasma cells and accumulates in bone marrow, according to the Mayo Clinic. Treatment options include bone marrow transplants, chemotherapy and radiation therapy.
News of the diagnosis rallied lawmakers to send well wishes to Mr. Scalise on X, the platform formerly known as Twitter. Many praised the majority leader as a fighter.
Mr. Scalise has faced adversity before — the lawmaker was shot and grievously wounded during an assassination attempt by a supporter of progressive Sen. Bernard Sanders during a congressional baseball practice in 2017. He returned to the House a few months later.
“Steve Scalise is a dear friend, and anyone who knows him knows he’s a faith-filled fighter who can overcome any obstacle that stands in his way,” said House Speaker Kevin McCarthy on X. “I spoke with him today and he’s in good spirits, as nothing — not a gunshot and certainly not cancer — will stop him from accomplishing what he sets his mind to.”
“There’s no one tougher than Steve Scalise,” said House Majority Whip Tom Emmer of Minnesota. “Our prayers are with Steve and his family and I have no doubt he will overcome adversity once again.”
“There is no stronger fighter than Steve Scalise,” said House Republican Conference Chair Rep. Elise Stefanik of New York. “Steve is as tough and kind as they come, and he has beaten so many unbeatable odds. The Legend from Louisiana is beloved by his colleagues and America and we know he will fight this next battle with that same resolve. We are proud to stand by to support Steve and his family as they embrace strength and faith in this next challenge.”
Mr. Scalise’s diagnosis comes as the House is set to return to work on Sept. 12 after a long summer break. House leadership will have to hustle to avoid a partial government shutdown before the Sept. 30 end of the current fiscal year.
So far, the lower chamber has advanced only one out of a dozen federal spending bills, while the Democrat-led Senate has advanced all 12 of its spending measures out of committee.
Front and center will be the fight over a stopgap spending measure known as a continuing resolution that will continue to fund the government until spending measures are advanced.
Mr. McCarthy, California Republican, and the rest of the House GOP leadership will wrestle with the House Freedom Caucus, which has given ultimatums for their support of the short-term funding measure.
The more than 40-member conservative caucus has pledged to not support a continuing resolution unless a trio of demands are met, which includes addressing issues at the U.S.-Mexico border, weaponization of the Department of Justice, and putting an end to “woke” Pentagon policies. Their demands also are dependent on rolling back federal spending to 2022 levels.
• Alex Miller can be reached at amiller@washingtontimes.com.
Please read our comment policy before commenting.